Hypereosinophilic syndrome posttreatment with triple-negative breast cancer

Hypereosinophilic syndrome posttreatment with triple-negative breast cancer

Therapy-related secondary hematological changes play a crucial role in determining the life span of an otherwise recovered cancer patient after successful treatment. Hypereosinophilic syndrome (HES) is a potentially life-threatening condition when left unmanaged. The exact etiology of HES, however,...

Full description

Bibliographic Details
Main Author: Khalid A AlSaleh
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2020-01-01
Series:Journal of Applied Hematology
Subjects:
fip1 like-1-platelet-derived growth factor receptor-alpha
hypereosinophilic syndrome
imatinib
leukocytosis
triple-negative breast cancer
Online Access:http://www.jahjournal.org/article.asp?issn=1658-5127;year=2020;volume=11;issue=2;spage=80;epage=83;aulast=AlSaleh

Internet

http://www.jahjournal.org/article.asp?issn=1658-5127;year=2020;volume=11;issue=2;spage=80;epage=83;aulast=AlSaleh

Similar Items